Overview
Prostate cancer is a malignancy arising from the epithelial cells of the prostate gland, most often as adenocarcinoma originating in the peripheral zone. It is among the most frequently diagnosed cancers in men and exhibits a wide biological spectrum, ranging from indolent tumors that may never become clinically significant to aggressive disease that metastasizes to bone and lymph nodes. Many prostate cancers are androgen-dependent, relying on signaling through the androgen receptor for growth, a feature that underlies both diagnosis and treatment strategy. Screening and detection commonly involve serum prostate-specific antigen measurement, digital rectal examination, and imaging, with definitive diagnosis established by biopsy and graded using the Gleason scoring system, which reflects the architectural differentiation of tumor tissue. Risk-stratified management ranges from active surveillance for low-risk disease to radical prostatectomy, external-beam or brachytherapy radiation, and androgen-deprivation therapy for advanced cases. Castration-resistant progression, in which tumors continue to grow despite low testosterone, has driven the development of novel hormonal agents, taxane chemotherapy, and targeted approaches. Research continues to refine molecular subtyping, identify prognostic biomarkers, and clarify the genetic and environmental factors that shape incidence and outcome. Early localized detection generally permits curative treatment.
Research published in this journal
5 peer-reviewed articles, ranked by relevance. Each links to its DOI.
Itraconazole Prophylaxis for an Outbreak of Invasive Aspergillosis in a Hematology Ward after Hospital Construction Work
Syndrome of inappropriate antidiuretic hormone secretion in a patient with a Nodular Lymphocyte-Predominant Hodgkin Lymphoma. A case report and review of literature
Combination of Radiation Therapy and Immunotherapy in the Treatment of Melanoma
Risk Factors Associated with Breast Cancer
How this research is being cited
The 5 articles above have been cited 11 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2024 · Expert Opinion on Drug Safety
-
2024 · Expert Opinion on Drug Safety
-
2023 · Siberian Journal of Oncology
-
2023 · Siberian journal of oncology
-
2022 · Effective Pharmacotherapy
-
B. Ellerin et al. · 2020 · Cancer Radiothérapie
-
2020 · Frontiers in Oncology
-
2020 · Cancer/Radiothérapie
A sample of recent works citing this journal's research on Oncology Prostate Cancer, linking to each citing work.